H. Schmoll

发表

J. Borrás, L. Påhlman, R. Beets-Tan, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

F. D. De Braud, E. Van Cutsem, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

J Ricke, T Maughan, W. Oyen, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types.

M. Aapro, H. Schmoll, F. Jahn, 2013, Cancer treatment reviews.

Advances in the Prognosis and Treatment of Medullary or Anaplastic Thyroid Cancer

W. Voigt, H. Schmoll, K. Jordan, 2008 .

First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial

C. Bokemeyer, L. Kanz, N. Schleucher, 2003, British Journal of Cancer.

Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.

W. Voigt, M. Yin, U. Vanhoefer, 1997, Anticancer research.

Predictive Tumor Markers

C. Sotiriou, L. V. Veer, M. Ignatiadis, 2016 .

Perioperative multimodal treatment of locally advanced rectal cancer. Results of a pilot study

J. Karstens, P. Schöffski, R. Pichlmayr, 1994 .

Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg

R. Labianca, D. Kerr, W. Scheithauer, 1998 .

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.

F. D. De Braud, E. Van Cutsem, J. Tabernero, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.

R. Labianca, D. Kerr, D. Sargent, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

5LBA First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study)

J. Tabernero, D. Haller, T. Price, 2009 .

Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.

W. Hohenberger, C. Rödel, G. Grabenbauer, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial

Y. Ko, P. Wernet, R. Souchon, 2005, The Lancet.

Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats

H. Holzhausen, M. Fittkau, W. Voigt, 2004, Journal of Cancer Research and Clinical Oncology.

Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.

W. Dempke, W. Voigt, T. Mueller, 2005, Anticancer research.

The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005.

R. Labianca, K. Haustermans, E. Van Cutsem, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Cytokines and cytotoxic agents in renal cell carcinoma: a review.

S. Seeber, H. Schmoll, M. Stahl, 1992, Seminars in oncology.

Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management.

D. Rades, W. Knapp, H. Schmoll, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.

M. O’connell, D. Haller, G. Yothers, 2014, The Lancet. Oncology.

Is there a standard adjuvant treatment for rectal cancer?

B. Nordlinger, K. Tveit, H. Schmoll, 1998, European journal of cancer.

Motivation to participate in cancer screening programmes.

H. Schmoll, D. Schwoon, Hans-Joachim-Schmoll, 1979, Social science & medicine.

Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity

P. Albers, H. Holzhausen, T. Mueller, 2010, Histochemistry and Cell Biology.

Loss of Oct-3/4 Expression in Embryonal Carcinoma Cells Is Associated with Induction of Cisplatin Resistance

W. Voigt, T. Mueller, H. Schmoll, 2006, Tumor Biology.

C. Bokemeyer, M. Krzakowski, M. Aapro, 2005, Oncology.

The Future Development of Bevacizumab in Colorectal Cancer

H. Schmoll, E. Díaz-Rubio, 2005, Oncology.

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

R. Labianca, D. Kerr, I. Nagtegaal, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

What Chemotherapy to Recommend in Metastatic Patients

A. Stein, H. Schmoll, 2018 .

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

E. Van Cutsem, P. Ruff, D. Cunningham, 2015, European journal of cancer.

Systemic treatment of liver metastases from colorectal cancer

A. Stein, H. Schmoll, 2013, Therapeutic advances in medical oncology.

Optimum Duration of Metastatic Colorectal Cancer Treatment

A. Stein, H. Schmoll, 2013, Current Colorectal Cancer Reports.

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

R. Salazar, E. Van Cutsem, G. Bodoky, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study.

J. Boice, H. Schmoll, A. Taylor, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials.

M. O’connell, D. Haller, G. Yothers, 2012 .

Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604)

S. Kubicka, W. Schmiegel, W. Freier, 2008 .

Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?

D. Sargent, H. Schmoll, 2007, The Lancet.

Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS).

J. Tabernero, D. Haller, J. Cassidy, 2010 .

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

A. Hinke, A. Grothey, W. Schmiegel, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The integration of targeted agents into systemic therapy of metastatic colorectal cancer.

D. Arnold, H. Schmoll, R. Siewczynski, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Are Capecitabine and 5FU Equivalent When Combined with Radiotherapy

A. Stein, H. Schmoll, 2018 .

Potential regional differences for the tolerability profiles of fluoropyrimidines.

E. Van Cutsem, J. Tabernero, J. Bertino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.

W. Scheithauer, C. Bokemeyer, C. Köhne, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.

R. Labianca, M. Buyse, L. Påhlman, 2007, Journal of the National Cancer Institute.

Chemotherapy in rectal cancer

D. Arnold, H. Schmoll, R. Siewczynski, 2005 .

Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.

F. Lordick, H. Hochster, Shengyan Hong, 2005, Clinical colorectal cancer.

How to Achieve Long-Term Survival in Patients with Metastatic Rectal Cancer?

A. Stein, H. Schmoll, 2012 .

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

A. Hinke, A. Tannapfel, T. Trarbach, 2015, The Lancet. Oncology.

S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008

T. Seufferlein, R. Sauer, R. Porschen, 2008, Zeitschrift fur Gastroenterologie.

[Update S3-guideline "colorectal cancer" 2008].

V. Heinemann, T. Seufferlein, W. Schmiegel, 2008, Zeitschrift fur Gastroenterologie.

Is there a standard adjuvant treatment for rectal cancer?: Arbiter:

H. Schmoll, 1998 .

Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer

J. Cassidy, H. Schmoll, E. Cutsem, 2008 .

Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?

E. Van Cutsem, J. Cassidy, H. Schmoll, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents.

H. Schmoll, 1996, European journal of cancer.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Polychemotherapy of Gastric Carcinoma

H. Schmoll, H. Wilke, U. Fink, 1989 .

Phase I /II T rial o f C apecitabine, O xaliplatin, a nd R adiation for R ectal C ancer

W. Hohenberger, C. Rödel, G. Grabenbauer, 2003 .

The evolving role of oxaliplatin in the management of colorectal cancer

C. Tournigand, A. de Gramont, A. Cervantes, 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Integrating oxaliplatin into the management of colorectal cancer.

J. Cassidy, H. Schmoll, 2001, The oncologist.

Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection

A. Stein, H. Schmoll, 2014, Nature Reviews Clinical Oncology.

Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.

H. Schmoll, 2003, Anti-cancer drugs.

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.

T. Gruenberger, H. Hurwitz, J. Bendell, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-Fluorouracil modulation in colorectal carcinoma experience of German investigators.

H. Schmoll, C. H. Kohne-Wompner, 1993, Advances in experimental medicine and biology.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

R. Labianca, R. Schilsky, J. Berlin, 2018, European journal of cancer.

S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug?

H. Schmoll, 2010, The Lancet. Oncology.

Rectal cancer and synchronous metastases: resection of primary tumor or not?

T. Trarbach, H. Schmoll, 2009, Gastroenterologie clinique et biologique.

CAIRO and FOCUS – Authors' reply

D. Sargent, H. Schmoll, 2007, The Lancet.

Reply to O. Gires et al

D. Arnold, H. Schmoll, 2010 .

German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors

C. Nies, O. Schober, M. Luster, 2013, Langenbeck's Archives of Surgery.

Accomplishments in 2007 in the management of advanced gastroesophageal cancer.

J. Ajani, H. Schmoll, 2008, Gastrointestinal cancer research : GCR.

High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer — a phase II study in elderly patients or patients with cardiac risk

H. Schmoll, M. Stahl, H. Wilke, 1990, Investigational New Drugs.

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

R. Labianca, A. Benson, J. Zalcberg, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

F. Cavalli, J. Panse, M. Falautano, 2022, Leukemia.

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

F. Cavalli, F. Angrilli, V. Torri, 2017, The Lancet. Haematology.

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

F. Cavalli, V. Torri, J. Panse, 2016, The Lancet. Haematology.

Presence of Mesenchymal Stem Cells in Human Bone Marrow After Exposure to Chemotherapy: Evidence of Resistance to Apoptosis Induction

T. Mueller, H. Schmoll, J. Luetzkendorf, 2006, Stem cells.

Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β1‐integrin‐dependent mechanism

C. Müller-Tidow, C. Wickenhauser, R. Benndorf, 2016, International journal of cancer.

Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer

A. Grothey, C. Thomssen, H. Koelbl, 2009, International Journal of Gynecologic Cancer.

Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer.

W. Voigt, H. Schmoll, K. Jordan, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Crizotinib in refractory ALK‐positive diffuse large B‐cell lymphoma: a case report with a short‐term response

A. Rosenwald, A. Mottok, H. Schmoll, 2014, European journal of haematology.

A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis

A. Hinke, A. Grothey, W. Voigt, 2007, Supportive Care in Cancer.

Cellular oncogenes in human teratocarcinoma cell lines.

H. Tesch, C. Bartram, D. Bronson, 1990, International journal of andrology.

Megestrol acetate in cancer cachexia.

H. Schmoll, H. Wilke, I. Wildfang, 1991, Seminars in oncology.

Treatment of testicular tumours based on risk factors.

H. Schmoll, 1999, Current opinion in urology.

Sequelae of treatment in long-term survivors of testis cancer.

S. Fosså, R. Motzer, C. Sternberg, 2011, European urology.

S3-Guidelines Colorectal Cancer 2004

T. Sauerbruch, M. Zeitz, W. Hohenberger, 2005 .

Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation.

H. Schmoll, P. Schöffski, H. Schmoll, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma

C. Bokemeyer, M. Kuczyk, H. Schmoll, 1994, Annals of Hematology.

Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG).

P. Albers, A. Hinke, K. Dieckmann, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparative activity of antiemetic drugs.

M. Aapro, H. Schmoll, K. Jordan, 2007, Critical reviews in oncology/hematology.

Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.

H. Schmoll, K. Jordan, C. Kasper, 2005, European journal of cancer.

[S3-Guidelines Conference "Colorectal Carcinoma" 2004].

T. Sauerbruch, M. Zeitz, W. Hohenberger, 2004, Zeitschrift fur Gastroenterologie.

Preoperative (“Neoadjuvant”) Chemotherapy in Locally Advanced Gastric Carcinoma

H. Schmoll, H. Wilke, U. Fink, 1989 .

Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.

A. Grothey, W. Voigt, T. Mueller, 2003, Cancer research.

Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk.

R. Talamini, E. Vaccher, A. Buonadonna, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab.

S. Hauptmann, J. Rüssel, A. Stein, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma

W. Voigt, T. Mueller, H. Schmoll, 2005, Journal of Cancer Research and Clinical Oncology.

Endocrinological late effects after chemotherapy for testicular cancer.

C. Bokemeyer, H. Schmoll, F. Schuppert, 1996, British Journal of Cancer.

Interdisciplinary Consensus on Diagnosis and Treatment of Testicular Germ Cell Tumors: Result of an Update Conference on Evidence–Based Medicine (EBM)

R. Souchon, H. Schmoll, S. Krege, 2001, European Urology.

Cardiotoxicity of 5‐fluorouracil in combination with folinic acid in patients with gastrointestinal cancer

W. Hiddemann, C. Bokemeyer, A. Mügge, 1993, Cancer.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

S. Fosså, S. Culine, A. Horwich, 2008, European urology.

Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.

P. Kantoff, G. Demetri, C. Bokemeyer, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.

C. Bokemeyer, M. Kuczyk, M. Candelaria, 1997, European journal of cancer.

Growth requirements, growth factor responsiveness, and growth factor secretion of three human embryonal carcinoma cell lines

C. Bokemeyer, H. Schmoll, W. Verbeek, 2004, Journal of Cancer Research and Clinical Oncology.

Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors.

C. Bokemeyer, M. Kuczyk, M. Candelaria, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24].

D. Aust, I. Nagtegaal, K. Haustermans, 2016, European journal of cancer.

Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.

M. Aapro, H. Schmoll, Li Zhang, 2015, The oncologist.

Administration of Chemotherapy by an Arteriovenous Fistula in a Patient with Metastatic Rectal Cancer after Life-Threatening, Port Thrombosis-Associated Cava Superior Syndrome

A. Stein, D. Arnold, H. Schmoll, 2012, Oncology Research and Treatment.

Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model

T. Mueller, H. Schmoll, Henrike Lucas, 2019, Molecules.

Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer.

C. Köhne, S. Seeber, H. Schmoll, 1996, The Journal of infusional chemotherapy.

Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.

I. Schedel, H. Deicher, H. Schmoll, 1988, European journal of cancer & clinical oncology.

No synergistic activity of epirubicin and interferon-α2b in the treatment of hepatocellular carcinoma

C. Bokemeyer, H. Schmoll, A. Harstrick, 1995, Cancer Chemotherapy and Pharmacology.

Is Continuous 24-Hour Infusion of 5-Fluorouracil plus High-Dose Folinic Acid Effective in Patients with Progressive or Recurrent Colorectal Cancer?

C. Bokemeyer, L. Kanz, C. Köhne, 1998, Oncology.

Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.

W. Hiddemann, B. Dörken, C. Bokemeyer, 1997, European journal of cancer.

Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.

W. Hiddemann, C. Köhne, D. Strumberg, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.

C. Köhne, P. Schöffski, H. Schmoll, 1996, The Journal of infusional chemotherapy.

Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis

R. Greil, A. Hinke, A. Grothey, 2005 .

Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines.

A. Grothey, W. Voigt, C. Hoang‐Vu, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I/II study of sequential, dose‐escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas

C. Bokemeyer, L. Kanz, L. Arseniev, 1997, Cancer.

Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP).

R. Labianca, D. Kerr, D. Sargent, 2014 .

Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).

F. D. De Braud, E. Van Cutsem, J. Tabernero, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

Karin Haustermans, Cornelis J H van de Velde, Vincenzo Valentini, 2014, European journal of cancer.

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

P. Galle, S. Al-Batran, J. Siveke, 2016, BMC Cancer.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative evaluation of capecitabine or infusional leucovorin/5-fluorouracil (LV/5-FU) with or without oxaliplatin (Ox) for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials.

M. O’connell, D. Haller, G. Yothers, 2012 .

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy.

E. Van Cutsem, M. Ducreux, J. Tabernero, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of testicular cancer and the development of secondary malignancies.

C. Bokemeyer, H. Schmoll, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial

S. Kubicka, F. Lordick, N. Niederle, 2005 .

A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results

F. Lordick, T. Seufferlein, C. Dittrich, 2005 .

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.

C. Tournigand, R. Goldberg, V. Heinemann, 2020 .

FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.

T. Gruenberger, H. Hurwitz, J. Bendell, 2020 .

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

R. Labianca, A. Benson, J. Zalcberg, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabine +/- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up.

K. Haustermans, E. Van Cutsem, B. Nordlinger, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.

N. Wolmark, E. Van Cutsem, R. Goldberg, 2019, Journal of Clinical Oncology.

Selective internal radiotherapy in advanced colorectal cancer: only for right-sided tumours?

H. Schmoll, 2017, The Lancet. Oncology.

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: final analyses

K. Haustermans, B. Nordlinger, M. Mauer, 2016 .

Current controversies in cancer : Is there a standard adjuvant treatment for colon cancer?

P. Rougier, M. Slevin, H. Schmoll, 1998 .

Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC)

A. Grothey, P. Reichardt, K. Ridwelski, 2001 .

FOCUS4: a new trial design for evaluation of targeted drugs in colorectal cancer?

H. Schmoll, 2017, The lancet. Gastroenterology & hepatology.

The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature.

A. Horwich, P. Albers, C. Bokemeyer, 2012, European urology.

Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.

K. Kawai, K. Fizazi, H. Schmoll, 2011, Urology.

Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma.

W. Siegert, F. Natt, L. Bergmann, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study

W. Voigt, D. Arnold, H. Wolf, 2010, Bone Marrow Transplantation.

A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours.

W. Siegert, A. Horwich, M. Marangolo, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.

W. Siegert, C. Bokemeyer, L. Kanz, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.

C. Bokemeyer, L. Weissbach, J. Beyer, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.

C. Bokemeyer, L. Kanz, N. Niederle, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.

H. Gerhartz, C. Bokemeyer, L. Kanz, 1998, Seminars in oncology.

Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

A. Horwich, R. Huddart, V. Kataja, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

V. Grünwald, H. Schmoll, J. Casper, 2004, Investigational New Drugs.

Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

A. Horwich, R. Huddart, V. Kataja, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

A. Horwich, R. Huddart, V. Kataja, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Hematopoietic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose-intensive chemotherapy

H. Einsele, C. Bokemeyer, M. Kuczyk, 2004, Annals of Hematology.

First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases.

C. Bokemeyer, L. Kanz, U. Rüther, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of brain metastases in patients with testicular cancer.

C. Bokemeyer, L. Kanz, B. Metzner, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials

A. Horwich, C. Meisner, C. Bokemeyer, 2004, British Journal of Cancer.

Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer.

C. Bokemeyer, M. Kuczyk, H. Schmoll, 1995, European journal of cancer.

Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines

C. Bokemeyer, H. Schmoll, A. Harstrick, 2004, Cancer Chemotherapy and Pharmacology.

Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.

Y. Rustum, H. Schmoll, A. Harstrick, 1993, European journal of cancer.

Current Treatment of Stage I Testicular Seminoma

H. Schmoll, K. Heissner, 2011, Oncology Research and Treatment.

Management of early stages of testicular carcinoma: the current status.

H. Schmoll, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S. Fosså, A. Horwich, V. Kataja, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Germ Cell Testis Tumors

P. Chung, H. Schmoll, 2006 .

Single‐agent carboplatinum for advanced seminoma a phase II study

C. Bokemeyer, R. Souchon, W. Berdel, 1993, Cancer.

Cell lines of human germinal cancer.

C. Fonatsch, H. Schmoll, J. Casper, 1987, International journal of andrology.

High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.

D. Huhn, W. Siegert, C. Bokemeyer, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.

S. Fosså, A. Dunant, S. Tjulandin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility of a combination of high dose chemotherapy ifosfamide, carboplatin, etoposide (ICE) plus stem cells and bevacizumab in refractory sarcoma and germ cell tumors

H. Schmoll, K. Jordan, L. Mueller, 2005 .

Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters

J. Serth, C. Bokemeyer, L. Kanz, 2005, Journal of Cancer Research and Clinical Oncology.

Bilateral testicular tumours: prevalence and clinical implications.

C. Bokemeyer, P. Schöffski, H. Schmoll, 1993, European journal of cancer.

Colorectal cancer: What is the role of lymph node metastases in the progression of colorectal cancer?

I. Nagtegaal, H. Schmoll, 2017, Nature Reviews Gastroenterology & Hepatology.

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.

K. Haustermans, E. Van Cutsem, B. Nordlinger, 2018 .

OC-0250: First results of the PETACC-6 randomized phase III trial in locally advanced rectal cancer

K. Haustermans, B. Nordlinger, R. Hofheinz, 2014 .

Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours

J. Serth, C. Bokemeyer, U. Jonas, 2005, Journal of Cancer Research and Clinical Oncology.

Prognostic factors for advanced seminoma--a solid basis for clinical trials.

H. Schmoll, 1997, European journal of cancer.

Single-Agent Carboplatinum for Advanced Seminoma

C. Bokemeyer, W. Berdel, K. Dieckmann, 1993 .

Acute and Late Toxicity on Peripheral Nerves After Chemotherapy — A Review

C. Bokemeyer, H. Schmoll, B. Frank, 1995 .

Production and pre-clinical significance of haematopoietic peptide growth factors (HPGF) in human non-seminomatous germ cell tumour cell lines

H. Schmoll, J. Casper, T. Dunn, 1998, Journal of Cancer Research and Clinical Oncology.

A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.

C. Bokemeyer, L. Weissbach, P. Schöffski, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds.

C. Paetz, T. Mueller, M. Luckner, 2003, Journal of inorganic biochemistry.

[Therapeutic application of mesenchymal stromal cells in autoimmune disease: rationale and initial clinical experience].

H. Schmoll, G. Keyßer, M. Schendel, 2009, Zeitschrift fur Rheumatologie.

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial

K. Haustermans, B. Nordlinger, M. Mauer, 2013 .

Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.

M. Rothenberg, H. Schmoll, N. Botwood, 2009, Clinical colorectal cancer.

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.

Keunchil Park, M. Aapro, J. von Pawel, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

A. Ganser, W. Hofmann, L. Bergmann, 2004, Annals of Hematology.

Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy

A. Grothey, H. Wolf, H. Schmoll, 2005, European journal of haematology.

Tolerability of fluoropyrimidines appears to differ by region.

E. Van Cutsem, D. Haller, L. Saltz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.

C. Bokemeyer, L. Kanz, M. Kuczyk, 1998, British Journal of Cancer.

Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer

J. Tabernero, D. Haller, A. Figer, 2005 .

Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis

C. Müller-Tidow, H. Schmoll, K. Jordan, 2015, Oncology.

Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts

C. Bokemeyer, H. Schmoll, J. Casper, 2004, Investigational New Drugs.

Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells

T. Mueller, H. Schmoll, J. Luetzkendorf, 2009, Cellular and Molecular Life Sciences.

Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients

A. Schauer, H. Schmoll, D. Marx, 2005, Journal of Cancer Research and Clinical Oncology.

Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein–Barr virus DNAemia

C. Lautenschläger, H. Schmoll, U. Bacher, 2013, Leukemia & lymphoma.

Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest

C. Müller-Tidow, N. Lambrecht, H. Schmoll, 2017, PloS one.

[Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms].

A. Grothey, H. Schmoll, L. Kellermann, 2002, Medizinische Klinik.

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

R. Greil, A. Hinke, A. Grothey, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantification of additional short arms of chromosome 12 in germ cell tumours using the polymerase chain reaction.

A. Nordheim, T. Strohmeyer, R. Janknecht, 1997, European journal of cancer.

Introduction

H. Schmoll, E. Díaz-Rubio, 2005, Oncology.

Synergistic cytotoxic effects of ether phospholipid analogues and ionizing radiation in human carcinoma cells.

O. Gründel, C. Hess, H. Schmoll, 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Modulation of cytotoxic drug activity by dipyridamole.

H. Schmoll, A. Harstrick, H. Wilke, 1990, Cancer treatment reviews.

VBAMDex chemotherapy in advanced multiple myeloma *

I. Schedel, H. Deicher, K. Schumacher, 1988, European Journal of Haematology.

Hepatic arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver metastases from colorectal carcinoma.

C. Bokemeyer, H. Schmoll, J. Hartmann, 1997, Oncology reports.

Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) vs. capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI study group

W. Schmiegel, W. Freier, A. Reinacher-Schick, 2007 .

174 Intensive chemotherapy (idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML

A. Ganser, F. Herrmann, W. Hofmann, 1997 .

Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis

S. Kubicka, A. Grothey, T. Seufferlein, 2004 .

Final safety findings from a randomized phase III trial of capecitabine + oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.

E. Van Cutsem, J. Tabernero, D. Haller, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural Interleukin-2 plus Lymphokine-Activated Killer Cells in Patients with Advanced Malignancy

H. Link, M. Freund, H. Mohr, 1990 .

Comparison of 5 vs 10 μg/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer

C. Bokemeyer, H. Schmoll, J. Beyer, 1993, Annals of Hematology.

Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma

W. Siegert, C. Bokemeyer, H. Schmoll, 2005, Journal of Cancer Research and Clinical Oncology.

Treatment intensification in disseminated germ-cell tumors

W. Siegert, C. Bokemeyer, H. Schmoll, 2004, World Journal of Urology.

Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents.

H. Schmoll, A. Harstrick, H. Wilke, 1990, European journal of cancer.

Phase II Evaluation of 5-Fluorouracil plus Folonic Acid and Alpha 2b-lnterferon in Metastatic Colorectal Cancer

W. Hiddemann, C. Bokemeyer, H. Rauschecker, 1997 .

Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.

H. Schmoll, A. Harstrick, J. Casper, 1987, International Journal of Andrology.

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.

K. Haustermans, E. Van Cutsem, B. Nordlinger, 2014 .

Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular‐cancer cell lines differing in their sensitivity to standard agents

H. Schmoll, A. Harstrick, H. Poliwoda, 1994, International journal of cancer.

Therapy of Advanced MDS, AML Evolving from MDS, or Secondary AML with Idarubicin Ara-C, VP-16, Followed by G-CSF-Priming Exhibits High Remission Rate

A. Ganser, F. Herrmann, W. Hofmann, 1998 .

“Tumor immunology meets oncology IV”, 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany

B. Seliger, H. Schmoll, D. Riemann, 2010, Cancer Immunology, Immunotherapy.

Cetuximab with oxaliplatin and capecitabine (CAPOX)in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy

W. Voigt, D. Arnold, U. Graeven, 2005 .

Therapy of Acquired Hemophilia - Immunoadsorption and Rituximab Treatment for Immunosuppression and Substitution of Coagulation Factors

H. Wolf, H. Schmoll, A. Harba, 2007 .

Evaluation of long-term toxicity after chemotherapy for testicular cancer.

C. Bokemeyer, M. Kuczyk, H. Schmoll, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of gefitinib in combination with oxaliplatin and weekly 5-FU/FA (FUFOX) for second-/third-line treatment in patients (pts) with metastatic colorectal cancer (CRC)

C. Bokemeyer, L. Kanz, H. Schmoll, 2005 .

Phase I study of gefitinib in combination with capecitabine and irinotecan for 2nd- and/or 3rd-line treatment in patients with metastatic colorectal cancer

T. Seufferlein, D. Arnold, H. Schmoll, 2005 .

Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.

W. Hiddemann, C. Bokemeyer, J. Preiß, 1992, Seminars in oncology.

Etoposide and Split‐Dose Cisplatin in Small‐Cell Lung Cancer

U. Gunzer, H. Schmoll, H. Wilke, 1988, American journal of clinical oncology.

Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001).

R. Labianca, D. Kerr, P. Johnston, 2002, European journal of cancer.

Orthopedic Knee Replacement in Hemophilic Patients

H. Schmoll, H. Wolf, H. Reichel, 2005 .

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

W. Siegert, S. Fosså, S. Culine, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, ESMO Open.

Long-term effects on sexual function and fertility after treatment of testicular cancer

C. Bokemeyer, M. Kuczyk, C. Kollmannsberger, 1999, British Journal of Cancer.

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

D. Sargent, R. Goldberg, A. Grothey, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S3-Leitlinie „Magenkarzinom” –

M. Ebert, H. Feußner, P. Malfertheiner, 2011 .

Cyclooxygenase-2: a novel target for cancer chemotherapy?

A. Grothey, W. Dempke, H. Schmoll, 2001, Journal of Cancer Research and Clinical Oncology.

Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours

P. Stern, P. Andrews, L. Looijenga, 1996, International journal of cancer.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

S. Fosså, S. Culine, A. Horwich, 2008, European urology.

Characterization of rearranged Y chromosomes in human testicular tumor cell lines.

G. Gradl, C. Fonatsch, J. Schmidtke, 1989, Cancer genetics and cytogenetics.

26 Cancer of the Testis

H. Schmoll, D. Hossfeld, 1994 .

Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult son.

C. Bokemeyer, M. Kuczyk, P. Schöffski, 1993, The Journal of urology.

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

D. Sargent, M. Shah, D. Haller, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Has the new TNM classification for colorectal cancer improved care?

I. Nagtegaal, P. Quirke, H. Schmoll, 2012, Nature Reviews Clinical Oncology.

Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.

A. Horwich, C. Bokemeyer, L. Kanz, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.

S. Fosså, A. Horwich, C. Bokemeyer, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting of neoglycoprotein-drug conjugates to cultured human embryonal carcinoma cells

C. Bokemeyer, H. Gabius, H. Schmoll, 2004, Journal of Cancer Research and Clinical Oncology.

Cell surface lectins of transplantable human teratocarcinoma cells: purification of a new mannan-specific endogenous lectin.

H. Gabius, F. Cramer, H. Schmoll, 1985, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

A. Horwich, R. Huddart, V. Kataja, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of a non-ras 21-kDa protein in patients with metastatic testicular germ-cell tumors

C. Bokemeyer, H. Schmoll, H. Poliwoda, 2005, Journal of Cancer Research and Clinical Oncology.

Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer.

W. Siegert, C. Bokemeyer, M. Kuczyk, 1995, Journal of the National Cancer Institute.

Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma.

C. Bokemeyer, H. Schmoll, M. Stahl, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

S. Culine, A. Horwich, P. Albers, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.

C. Meisner, C. Bokemeyer, L. Kanz, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables.

A Kramar, W. Siegert, C. Bokemeyer, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines

H. Schmoll, A. Harstrick, H. Wilke, 2004, Investigational New Drugs.

Human Chorionic Gonadotropin-Induced Hyperthyroidism in Germ Cell Cancer – a Case Presentation and Review of the Literature

W. Voigt, H. Wolf, H. Schmoll, 2007, Oncology Research and Treatment.

A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer.

C. Erlichman, B. Gustavsson, H. Schmoll, 1996, American journal of clinical oncology.

A review of the evolution of systemic chemotherapy in the management of colorectal cancer.

N. Petrelli, B. Gustavsson, K. Tveit, 2015, Clinical colorectal cancer.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

J. Hecht, R. Salazar, E. Van Cutsem, 2012, The Lancet. Oncology.

Improving outcomes in colorectal cancer: where do we go from here?

J. Borrás, E. Van Cutsem, M. Ducreux, 2013, European journal of cancer.

Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations.

H. Schmoll, K. Jordan, C. Sippel, 2007, The oncologist.

The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiation

T. Mueller, R. Dammann, H. Schmoll, 2009, Cell cycle.

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.

R. Labianca, D. Kerr, K. Haustermans, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Trials in Patients with Carcinoma of an Unknown Primary Site: The Past, the Present, and the Future

K. Fizazi, H. Schmoll, 2006 .

EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe.

J. Borrás, J. Coebergh, L. Påhlman, 2013, European journal of cancer.

S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII).

V. Heinemann, T. Sauerbruch, C. Rödel, 2010, Zeitschrift fur Gastroenterologie.

Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.

C. Bokemeyer, L. Kanz, P. Biron, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer

S. Seeber, H. Schmoll, M. Stahl, 2004, Cancer Chemotherapy and Pharmacology.

Etoposide, Leukovorin and 5-Fluorouracil (ELF) in Advanced Gastric Carcinoma – Final Results of a Phase-II Study in Elderly Patients or Patients with Cardiac Risk

H. Schmoll, M. Stahl, A. Harstrick, 1991 .

Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.

W. Voigt, D. Arnold, H. Schmoll, 2006, The oncologist.

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.

U. Gunnarsson, M. Piccart-Gebhart, M. Paesmans, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2).

J. Borrás, L. Påhlman, K. Haustermans, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Safety and efficacy of weekly 5-fluorouracil/ folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer

W. Voigt, A. Stein, D. Arnold, 2010, Therapeutic advances in medical oncology.

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

R. Labianca, J. Berlin, K. Haustermans, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence

T. Mueller, H. Schmoll, H. Caysa, 2009, Journal of cellular and molecular medicine.

MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach

E. Van Cutsem, M. Ducreux, J. Tabernero, 2018, Journal of Cancer Research and Clinical Oncology.

C. Tournigand, R. Labianca, J. Ajani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pancreatic cancer treatment and research: an international expert panel discussion.

J. Berlin, E. Van Cutsem, M. Ducreux, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

C. Tournigand, D. Sargent, M. Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity

W. Voigt, C. Müller-Tidow, T. Mueller, 2017, PloS one.

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of

E. Van Cutsem, B. Nordlinger, M. Ducreux, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours.

W. Siegert, C. Bokemeyer, W. Berdel, 1993, European journal of cancer.

Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.

I. Petersen, J. Rüssel, D. Niederwieser, 2020, JAMA oncology.

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

C. Tournigand, M. Buyse, C. Bokemeyer, 2019, JAMA network open.

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012

R. Labianca, M. Büchler, J. Berlin, 2013 .

Cerebral Sinus Thrombosis after Asparaginase Therapy

W. Voigt, H. Wolf, H. Schmoll, 2001 .

Side-effects of GM-CSF treatment in advanced testicular cancer.

C. Bokemeyer, H. Schmoll, A. Harstrick, 1993, European journal of cancer.

OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.

S. Curley, J. Kahan, B. Nordlinger, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Therapy for Early Colon Cancer

A. Stein, H. Schmoll, S. Hiemer, 2011, Drugs.

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

J. Hardwick, J. Boice, H. Schmoll, 2010, Supportive Care in Cancer.

Cisplatin resistance and oncogenes - a review

A. Grothey, B. Hill, W. Dempke, 2000, Anti-cancer drugs.

The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.

R. Labianca, D. Kerr, P. Johnston, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance

R. Pieters, K. Sikora, W. Siegert, 1991, Journal of Cancer Research and Clinical Oncology.

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

W. Scheithauer, F. Mayer, B. Wittig, 2014, Journal of Cancer Research and Clinical Oncology.

Metastases to the breast from non-mammary malignancies: primary tumors, prevalence, clinical signs, and radiological features.

R. Spielmann, H. Holzhausen, H. Schmoll, 2011, Academic radiology.

Intermediate-dose Cytarabine Treatment Delivered at Moderate Infusion Rates for De Novo Acute Myeloid Leukemia-Results of a phase I-II Study

D. Hasenclever, D. Niederwieser, R. Krahl, 2002, Leukemia and Lymphoma.

Anthracycline extravasation injuries: management with dexrazoxane

H. Schmoll, K. Jordan, T. Behlendorf, 2009, Therapeutics and clinical risk management.

TCRM-3694-anthracycline extravasation

H. Schmoll, K. Jordan, T. Behlendorf, 2009 .

Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL)

W. Hiddemann, M. Schäfers, M. Freund, 1992, Annals of Hematology.

CD34+ Hematopoietic Progenitor Cells Express CD 184 Antigen and to a Minor Extend MMP9.

H. Wolf, H. Schmoll, J. Abendroth, 2007 .

MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside.

W. Scheithauer, B. Wittig, H. Schmoll, 2015, Critical reviews in oncology/hematology.

IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma.

J. Trojan, M. Schroff, B. Wittig, 2012, Journal of Clinical Oncology.

Preliminary results of an ongoing phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line induction therapy (IMPACT Study).

W. Scheithauer, F. Mayer, M. Schroff, 2011, Journal of Clinical Oncology.

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials

A. Degramont, J. Meyerhardt, C. Bokemeyer, 2022, JNCI Cancer Spectrum.

Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.

J Schleicher, C. Bokemeyer, L. Kanz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality assurance in the treatment of colorectal cancer: the EURECCA initiative.

C. V. D. van de Velde, V. Valentini, P. G. Boelens, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer.

D. Aust, I. Nagtegaal, K. Haustermans, 2016, European journal of cancer.

Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus

C. Bokemeyer, H. Schmoll, M. Stahl, 2004, Cancer Chemotherapy and Pharmacology.

Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC).

C. Bokemeyer, H. Schmoll, 1993, European urology.

[S3-guideline colorectal cancer version 1.0].

W. Hohenberger, K. Schulmann, W. Schmiegel, 2013, Zeitschrift fur Gastroenterologie.

Detection of an occult B-cell lymphoma in the donor's bone marrow prior to HLA-matched sibling transplantation.

W. Voigt, H. Wolf, H. Schmoll, 2002, Journal of hematotherapy & stem cell research.

Current results of a multicenter trial in multiple myeloma.

I. Schedel, H. Deicher, M. Gramatzki, 1986, Onkologie.

The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer.

C. Bokemeyer, H. Schmoll, M. Stahl, 1992, Seminars in oncology.

Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.

E. Van Cutsem, J. Tabernero, D. Haller, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).

L. Collette, C. Bokemeyer, M. D. De Santis, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

The use of carboplatin in malignant germ cell tumours.

C. Bokemeyer, H. Schmoll, A. Harstrick, 1994, European journal of cancer.

F.L. Greene, D.L. Page, I.D. Fleming et al. (eds). AJCC Cancer Staging Manual, 6th edition

H. Schmoll, H.-J. Schmoll, 2003 .

Metoclopramide versus setrons in delayed emesis in moderate emetogenic chemotherapy: A meta-analysis.

A. Hinke, F. Roila, P. Feyer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer

E. Van Cutsem, J. Tabernero, Tae Won Kim, 2020, JAMA network open.

Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial

O. Kuss, H. Schmoll, K. Jordan, 2009, Supportive Care in Cancer.

Waterfall plot analysis of XELOX or XELIRI with cetuximab or bevacizumab in patients with advanced colorectal cancer (ACRC): Combined analysis of two randomized first-line phase II trials of the AIO CRC study group

S. Kubicka, A. Hinke, V. Heinemann, 2008 .

Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas.

C. Bokemeyer, P. Schöffski, H. Schmoll, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature

A. Wienke, B. Hildebrandt, S. Hollerbach, 2012, BMC Cancer.

Reply to P. Potemski and K. Bujko.

M. Mauer, H. Schmoll, S. Marréaud, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor-activity and toxicity of continuous-infusion versus bolus administration of bleomycin in 2 heterotransplanted human testicular cancer cell-lines.

C. Bokemeyer, E. Ludwig, H. Schmoll, 1995, Oncology reports.

Severe thrombocytosis and anemia associated with celiac disease in a young female patient: a case report

W. Voigt, H. Wolf, H. Schmoll, 2008, Journal of medical case reports.

Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours.

C. Bokemeyer, H. Schmoll, H. Schmoll, 1992, European journal of cancer.

Update on capecitabine in colorectal cancer.

D. Arnold, H. Schmoll, 2006, The oncologist.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

C. Tournigand, D. Sargent, C. Bokemeyer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

“CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.

J. Rüssel, B. Hildebrandt, A. Stein, 2017 .

Effects of behavioral intervention on plasma cortisol and lymphocytes in breast cancer patients: An exploratory study

M. Schedlowski, H. Schmoll, U. Tewes, 1994 .

Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN)

T. Seufferlein, H. Dralle, D. Vordermark, 2015, BMC Cancer.

The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination

H. Schmoll, K. Jordan, P. Jahn, 2011, Bone Marrow Transplantation.

Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy.

W. Voigt, H. Wolf, H. Schmoll, 2009, European journal of cancer.

Disseminated testicular cancer with bulky disease: results of a phase-II study with cisplatin ultra high dose/VP-16/bleomycin.

L. Bergmann, J. Preiß, H. Schmoll, 1987, International journal of andrology.

What Is the Ongoing Recommendation in the Management of Rectal Cancer

C. Velde, V. Valentini, H. Schmoll, 2012 .

Secondary neoplasms following treatment of malignant germ cell tumors.

C. Bokemeyer, H. Schmoll, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.

R. Greil, A. Hinke, A. Grothey, 2008, Clinical colorectal cancer.

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

J. Hecht, C. Bokemeyer, E. Van Cutsem, 2021, Therapeutic advances in medical oncology.

Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events

A. Wienke, R. Spielmann, H. Schmoll, 2014, Acta radiologica.

The role of ifosfamide in testicular cancer.

H. Schmoll, H J Schmoll, 1987, Seminars in oncology.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

C. Tournigand, D. Sargent, R. Simes, 2018, Journal of the National Cancer Institute.

Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.

O. Margalit, N. Wolmark, D. Haller, 2021, Clinical colorectal cancer.

Benefits and Risks of Colorectal Cancer Screening

K. Giersiepen, M. Kallenbach, J. Riemann, 2014, Oncology Research and Treatment.

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.

W. Hiddemann, B. Dörken, C. Köhne, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer.

E. Van Cutsem, M. Ducreux, J. Tabernero, 2021 .

The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.

R. Labianca, D. Kerr, W. Scheithauer, 2008, Annals of Oncology.

PG 6.2 Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis

K. Haustermans, B. Nordlinger, M. Mauer, 2014 .

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

R. Labianca, D. Kerr, J. Berlin, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Current treatment of high risk testis cancer.

H. Schmoll, K. Jordan, 2009, European journal of cancer.

Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support.

C. Meisner, C. Bokemeyer, L. Kanz, 2003, European journal of cancer.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European Journal of Cancer.

Interferon-α2b in Patients with Endocrine Active Tumors

H. Schmoll, M. Stahl, H. Wilke, 1990 .

Cancer of unknown primary (CUP)

G. Hübner, H. Schmoll, I. Wildfang, 2014, best practice onkologie.

FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in left-sided RAS/BRAF wild-type metastatic colorectal cancer patients: a propensity score-based analysis.

L. Boni, J. Bendell, D. Rossini, 2020, The oncologist.

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.

N. Tomita, T. Yamanaka, N. Wolmark, 2021, Journal of the National Cancer Institute.

Guidelines of the DGVS

T. Sauerbruch, M. Zeitz, W. Schmiegel, 2000 .

Targeting HER2: precision oncology for colorectal cancer.

H. Schmoll, 2016, The Lancet. Oncology.

Do we need oncology trials tailored for the elderly or frail?

H. Schmoll, 2011, The Lancet.

A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression

L. Stalpers, D. Rades, J. Karstens, 2004, Cancer.

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.

M. O’connell, D. Haller, G. Yothers, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting.

A. Grothey, C. Lautenschläger, H. Schmoll, 2010, European journal of cancer care.

[Interdisciplinary consensus on diagnosis and therapy of testicular tumors. Results of an update conference based on evidence-based medicine. German Testicular Cancer study Group (GTCSG)].

P. Albers, C. Bokemeyer, M. Kuczyk, 2000, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

The Role of Second-Line Chemotherapy in Colorectal Cancer

H. Schmoll, T. Büchele, C. Schöber, 1997 .

Treatment of Adolescents and Young Adults (AYA) with Cancer in a Multidisciplinary Setting: On the Way to a Highly Specialized AYA Unit

D. Körholz, H. Schmoll, T. Bernig, 2013, Klinische Pädiatrie.

The future of colorectal cancer research: an interview with.

H. Schmoll, 2020, Future oncology.

The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.

C. Bokemeyer, E. Ludwig, H. Schmoll, 1994, British Journal of Cancer.

Pazopanib vs pazopanib + gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO.

J. Rüssel, P. Reichardt, A. Stein, 2016 .

Treatment strategies in metastatic testicular cancer.

C. Bokemeyer, H. Schmoll, 1993, European urology.

MRI rectal cancer in Australia and New Zealand: An audit from the PETACC‐6 trial

T. Price, N. Tebbutt, H. Schmoll, 2016, Journal of Medical Imaging and Radiation Oncology.

Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.

Qian Shi, Daniel J. Sargent, Fang-Shu Ou, 2017 .

Gastric Carcinoma

H. Schmoll, H. Meyer, Hans-Joachim Schmoll, 1989, Springer New York.

Folinic acid (CF)/5-fluorouracil (FUra) combinations in advanced gastrointestinal carcinomas.

M. Freund, H. Schmoll, M. Stahl, 1988, Advances in experimental medicine and biology.

Analysis of Risk Factors for Cisplatin-Induced Ototoxicity in Patients With Testicular Cancer

L. Kanz, M. Kuczyk, C. Kollmannsberger, 1998 .

Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour.

C. Bokemeyer, C. Fonatsch, M. Freund, 1992, Annals of Oncology.

First-Line High-Dose Chemotherapy for ’Poor Risk’ Metastatic Non-Seminomatous Testicular Germ Cell Tumors

B. Kempf, H. Gerhartz, C. Bokemeyer, 1998, Oncology Research and Treatment.

Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.

R. Labianca, D. Sargent, E. Van Cutsem, 2016, Journal of geriatric oncology.

Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients with Elevated CEA.

C. Tournigand, J. Hecht, J. Douillard, 2020, Journal of the National Cancer Institute.

2-(4-(Tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II): a novel platinum compound that overcomes cisplatin resistance and induces apoptosis by mechanisms different from that of cisplatin.

W. Voigt, C. Kloft, T. Mueller, 2008, Journal of Medicinal Chemistry.

A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma.

M. Freund, H. Schmoll, M. Stahl, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases.

G. Behre, H. Schmoll, G. Keyszer, 2011, Arthritis and rheumatism.

Ototoxicity following therapy for testicular cancer

C. Bokemeyer, H. Schmoll, H. Poliwoda, 1993 .

Nephrotoxicity of cis-diamminedichloroplatinum with or without ifosfamide in cancer treatment.

H. Schmoll, H. Stolte, J. Alt, 1983, Clinical physiology and biochemistry.

Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study

T. Seufferlein, R. Hofheinz, A. Stein, 2014, Acta oncologica.

Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases.

C. Bokemeyer, H. Schmoll, J. Hartmann, 1998, European journal of cancer.

Immunosuppressive Treatment in Acquired von-Willebrand's Syndrome

H. Wolf, H. Schmoll, A. Frühauf, 2006 .

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.

R. Salazar, E. Van Cutsem, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of patients with cisplatin‐refractory testicular germ‐cell cancer

C. Bokemeyer, L. Kanz, C. Kollmannsberger, 1999 .

Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.

J. Lorch, H. Schmoll, T. Thomas, 2007, Cancer research.

[Specific treatment situations in metastatic colorectal cancer].

H. Amthauer, T. Seufferlein, W. Knoefel, 2010, Onkologie.

Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).

C. Bokemeyer, L. Kanz, C. Kollmannsberger, 1999, International journal of cancer.

CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209).

J. Rüssel, B. Hildebrandt, A. Stein, 2017 .

Right flank pain and high fever in a neutropenic patient with acute lymphoblastic leukaemia

M. Vehreschild, H. Schmoll, A. Surov, 2013, Mycoses (Berlin).

P. Galle, S. Al-Batran, J. Siveke, 2016, BMC Cancer.

Phase II study of carboplatin in untreated inoperable advanced stomach cancer.

H. Schmoll, M. Stahl, H. Wilke, 1990, European journal of cancer.

Experimental Approach for Assessment of Tumor Biology in Clinical Stage I Nonseminomatous Germ Cell Tumors (NSGCT)

C. Stief, C. Wittekind, H. Schmoll, 1991 .

[S3-guideline conference "Colorectal Cancer" 2004].

T. Sauerbruch, M. Zeitz, W. Hohenberger, 2005, Deutsche medizinische Wochenschrift.

[Results of treatment in primary disseminated osteosarcoma. Analysis of the follow-up of patients in the cooperative osteosarcoma studies COSS-80 and COSS-82].

H. Jürgens, V. Gerein, U. Bode, 1989, Onkologie.

Which Side Effect Related to Chemotherapy Should Be Described to the Patients Before Treatment

A. Stein, H. Schmoll, 2018 .

Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.

K. Haustermans, E. Van Cutsem, B. Nordlinger, 2020, Journal of Clinical Oncology.

Short report: High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: A phase II study

C. Bokemeyer, H. Schmoll, M. Stahl, 1990 .

Treatment of Relapsed Nonseminomatous Germ Cell Tumors with Vinorelbine: A Trial of the Phase 1/11 Study Group of the Association for Medical Oncology of the German Cancer Society

C. Bokemeyer, J. Droz, H. Schmoll, 1993 .

Pharmacokinetics of liposome encapsulated cisplatin in rats.

H. Schmoll, J. Freise, P. Magerstedt, 1982, Archives internationales de pharmacodynamie et de therapie.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

W. Oyen, R. Labianca, W. Scheithauer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

L. Collette, I. Skoneczna, H. Schmoll, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.

L. Ameye, S. Dolci, M. Skrzypski, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer.

H. Schmoll, E. Díaz-Rubio, 2005, Oncology.

LBA-10MODUL – A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1st-Line Maintenance Treatment of Metastatic Colorectal Cancer (mCRC): A Highly Adaptable Signal-Seeking Approach

M. Ducreux, A. Grothey, P. O'dwyer, 2015 .

Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.

D. Sargent, M. Buyse, C. Fuchs, 2013 .

When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab.

D. Arnold, H. Schmoll, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations.

H. Schmoll, K. Jordan, C. Sippel, 2007, The oncologist.

Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

A. Horwich, V. Kataja, C. Bokemeyer, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.

E. Ludwig, H. Schmoll, A. Harstrick, 1994, British Journal of Cancer.

Associations between the EGFR status as well as KRAS mutations and clinical outcome in colorectal cancer (CRC) patients (pts) treated with erlotinib monotherapy in 2nd or 3rd line—A study of the Arbeitsgemeinschaft Internistische

S. Kubicka, F. Lordick, N. Niederle, 2008 .

Cocultivation of Hematopoietic Cells in a Fluidized Bed Reactor

C. Wandrey, W. Ebell, H. Schmoll, 1997 .

Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab.

S. Hauptmann, J. Rüssel, A. Stein, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: A randomized placebo-controlled multicentric AIO phase II trial.

S. Al-Batran, J. Siveke, H. Schmoll, 2013 .

O-0017PREOPERATIVE CHEMORADIOTHERAPY AND POSTOPERATIVE CHEMOTHERAPY WITH CAPECITABINE AND OXALIPLATIN VS. CAPECITABINE ALONE IN LOCALLY ADVANCED RECTAL CANCER: DISEASE FREE SURVIVAL AT INTERIM ANALYSIS

K. Haustermans, B. Nordlinger, M. Mauer, 2014 .